Toronto, Ontario- Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:CA) (TLTFF) , a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed Michael Borovec as the Director of Investor Relations for the Company.
Michael possesses over 10 years’ experience in investor relations and capital markets. He successfully completed the Canadian Securities Course, as well as his Series 7, 22 and 63 US licences in 2001. Michael graduated with a Business Management degree from Humber College in 1999 and an International Politics degree from York University in 2005.
Roger Dumoulin-White, President and CEO, Theralase stated, “Michael has a strong working knowledge of the financial markets, security regulations and investor relations, with a demonstrated track record in serving as a corporate spokesman in the investor community. Michael’s main role with the organization will be to provide strategic corporate updates to the investment community, on a timely basis, in order to provide investors with the latest news about Theralase and our opportunities for growth. Michael will also be responsible for laying the groundwork for the Company to graduate to the Toronto Stock Exchange and eventually the NASDAQ stock exchange.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®”) (TLT:CA) (TLTFF) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50® company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer